

# 1 Evaluating scope and bias of population-level measles 2 serosurveys: a systematic review and bias assessment

3  
4 Alyssa N. Sbarra, MPH<sup>1,2\*</sup>, Prof. Felicity T. Cutts, MD<sup>1</sup>, Han Fu, PhD<sup>1</sup>, Ishu Poudyal,  
5 BA<sup>2</sup>, Dale Rhoda, M.S.<sup>3</sup>, Jonathan F. Mosser, MD<sup>2,4†</sup>, Prof. Mark Jit, PhD<sup>1†</sup>

6  
7 <sup>1</sup> Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical  
8 Medicine, London, UK

9 <sup>2</sup> Institute of Health Metrics and Evaluation, University of Washington, Seattle, WA, USA

10 <sup>3</sup> Biostat Global Consulting, Worthington, OH, USA

11 <sup>4</sup> Department of Health Metrics Sciences, University of Washington, Seattle, WA, USA

12  
13 † Authors contributed equally

14  
15 \* Corresponding author  
16 [alyssa.sbarra@lshtm.ac.uk](mailto:alyssa.sbarra@lshtm.ac.uk)

## 17 Abstract

18

19 Background: Measles seroprevalence data has potential to be a useful tool for understanding  
20 transmission dynamics and for decision making efforts to strengthen immunization programs. In  
21 this study, we conducted a systematic review and bias assessment of all primary data on  
22 measles seroprevalence in low- and middle-income countries published from 1962 to 2021.

23

24 Methods: On March 9, 2022, we searched PubMed for all available data. We included studies  
25 containing primary data on measles seroprevalence and excluded studies if they were clinical  
26 trials or brief reports, from only health care workers, suspected measles cases, or only  
27 vaccinated persons. We extracted all available information on measles seroprevalence, study  
28 design, and seroassay protocol. We conducted a bias assessment based on multiple categories  
29 and classified each study as having low, moderate, severe, or critical bias. This review was  
30 registered with PROSPERO (CRD42022326075).

31

32 Findings: We identified 221 relevant studies across all World Health Organization regions,  
33 decades and unique age ranges. The overall crude mean seroprevalence across all studies was  
34 78.00% (SD: 19.29%) and median seroprevalence was 84.00% (IQR: 72.75 – 91.66%). We  
35 classified 80 (36.2%) studies to have severe or critical overall bias. Studies from country-years  
36 with lower measles vaccine coverage or higher measles incidence had higher overall bias.

37

38 Interpretation: While many studies have underlying bias, many studies provide data that can be  
39 used to inform modelling efforts to examine measles dynamics and programmatic decisions to  
40 reduce measles susceptibility.

41

42 Funding: Bill & Melinda Gates Foundation; Gavi, the Vaccine Alliance; US National Institutes of  
43 Health

## 44 Research in Context

### 45 *Evidence before this study*

46 On August 20, 2023, we searched PubMed for systematic reviews published from January 1,  
47 1980 to August 20, 2023 using the search terms “measles” AND “sero\*”. We included studies if  
48 they were a systematic review of measles seroprevalence data and excluded studies that did  
49 not contain information on measles seroprevalence, were not systematic reviews, only included  
50 data from persons within a subpopulation (e.g., pregnant people or healthcare workers), or were  
51 of head-to-head laboratory comparisons of assay methodology. We identified one previous  
52 systematic review, by Thompson and Odahowski, published in 2016 and including data through  
53 mid-2014. That review identified 220 measles and/or rubella seroprevalence studies from all  
54 countries globally. Study authors published a descriptive summary of seroprevalence trends by  
55 age in a five select countries and a narrative summary of high-level epidemiologic trends in the  
56 underlying data, including information available on maternal antibody waning. Beyond these  
57 select summary findings, that study did not separately report seroprevalence from each study  
58 identified in the analysis, nor did it include any information on study design or population-  
59 representativeness. While study authors noted general limitations related to the different  
60 methods used across studies, they did not include any specific information on assay type,  
61 selection biases or other characteristics that could influence the accuracy of results or include  
62 data in a tabular format, which limits the utility of this study for subsequent analyses.

### 63 *Added value of this study*

64 Our study builds upon the known body of data on measles seroprevalence from low- and  
65 middle-income countries in multiple ways. First, we included data published up to December 31,  
66 2021 and from non-English language studies. Second, we extracted all available relevant  
67 information on study design characteristics and assay protocol used in each study to measure  
68 seroprevalence. Then, we constructed a bias assessment framework and conducted a bias  
69 assessment across multiple categories (study selection of participants, measurement tool and  
70 classification of immunity, and reporting of results) to classify the underlying bias in each study.  
71 Finally, we compared seroprevalence estimates across regions and bias levels, and bias levels  
72 among various study location characteristics.

### 74 *Implications of all the available evidence*

75 Accounting for study design and seroassay protocol used in serosurveys can influence  
76 interpretation of population-level seroprevalence estimates. Our systematic review and bias  
77 assessment provides an updated landscape of serological studies and highlights key biases in  
78 the current literature. It provides a repository of measles seroprevalence data, along with  
79 corresponding critical information on factors that influence population-representativeness and  
80 overall sensitivity of the measurement assay used in each study, that can be used to inform  
81 measles susceptibility estimates useful for planning targeted vaccination efforts.

83

## 84 Introduction

85 Measles remains a substantial cause of global morbidity and mortality<sup>1</sup>, especially in low- and  
86 middle-income settings where over 99% of measles cases and deaths occur<sup>2</sup>, despite the  
87 availability of a safe and effective vaccine<sup>3</sup>. Because ongoing measles transmission can be  
88 maintained if herd immunity (i.e., when the proportion of the population immune is sufficient to  
89 limit disease spread) has not been reached and sustained, estimating the proportion of people  
90 susceptible within a community is essential to plan immunization programs and assess future  
91 risk of measles outbreaks and deaths. However, due to factors such as timeliness of and age at  
92 vaccination<sup>4</sup>, disruptions to cold chains<sup>5</sup>, a lack of seroconversion in specific subpopulations  
93 (e.g., among persons living with human immunodeficiency virus (HIV)<sup>6</sup>), and variable  
94 surveillance systems across locations and time, inferring population-level measles immunity  
95 from a combination of vaccination coverage and case notifications can be challenging<sup>7</sup>.  
96 Alternatively, serosurveys can provide a snapshot of immunity gaps that remain in a community  
97 by determining population-level prevalence of IgG antibody levels above specific thresholds that  
98 suggest clinical protection against disease.

99  
100 As such, seroprevalence data can be used as tools to guide decisions<sup>1</sup> to and strengthen  
101 immunization programs, as inputs to dynamic models of disease transmission, and additionally  
102 to provide insights into vaccine field effectiveness and assessment of case ascertainment  
103 rates<sup>7,8</sup>. The interpretation of seroprevalence data is complicated, however, because of the  
104 potential for bias. Some of this bias can be due to inadequate sensitivity of laboratory assays<sup>9</sup>  
105 and/or specimen types<sup>10</sup> used for measuring antibody levels. Additionally, bias from assay  
106 procedures can be suspected when protocols or commercial details are not reported or if no  
107 quality control was performed. Furthermore, population-based surveys have the potential for  
108 additional bias to be introduced in the selection of participants or from lack of  
109 representativeness of the selected sample from the community.

110  
111 Beyond understanding the selection processes and laboratory assays used, it is critical to also  
112 consider how results of the serosurveys are reported. Considerations include what threshold of  
113 antibody titer was used as a correlate of clinical protection and how some tests report  
114 indeterminate results. In order to responsibly use and accurately interpret seroprevalence data  
115 for decision making or for modelling exercises, these issues need to be transparently  
116 acknowledged and discussed.

117  
118 A more in-depth understanding of available seroprevalence data across locations and time, as  
119 well as the related implications, is critical for using these historic data to calibrate models used  
120 to inform decision making for immunization program strengthening, especially in low- and  
121 middle-income countries (LMICs) that face the highest ongoing measles burden. To fill these  
122 gaps, we first conducted a systematic review of literature reporting measles seroprevalence  
123 data published through 2021 and extracted information on key study and assay information.  
124 Then, we developed a pilot bias assessment tool to assess the risk of bias in each study across  
125 the following categories: study selection of participants, measurement tool and classification of  
126 immunity, and results reporting.

## 127 128 Methods

### 129 *Search strategy and selection criteria*

130 This study follows PRISMA guidelines (Supplementary Tables 1-2) and was registered with  
131 PROSPERO (CRD42022326075). We performed a systematic review of published literature in  
132 any language containing information on population-level measles seroprevalence in LMICs. We

133 searched PubMed on March 9, 2022 for primary data published through December 31, 2021  
134 using the following search string:

135  
136 (((Measles) AND (seroprevalence OR sero-prevalence OR seropositive OR sero-positive  
137 OR seronegative OR sero-negative OR seroepidemiology OR sero-epidemiology OR  
138 seroprofile OR seroimmunity OR sero-immunity))  
139 OR ("Measles/epidemiology"[MeSH] AND (antibod\* OR serolog\*)))  
140 AND ("1900"[Date - Publication] : "2021"[Date - Publication])

141  
142 One individual (ANS) screened titles and abstracts for each study in the search results. For  
143 relevant studies, one of multiple individuals (ANS, HF, IP) reviewed the full-text of each to  
144 determine their inclusion or exclusion. We included studies that contained original data on  
145 measles antibody prevalence and excluded studies if they only contained data from high-income  
146 locations (as based on WorldBank 2021 income classifications<sup>11</sup>), did not contain data on  
147 measles IgG antibody, were based on non-original data or from non-human subjects, contained  
148 only results from laboratory assay development or clinical trials (including studies only  
149 containing information on vaccinated persons), studied a target population of only health-care  
150 workers or active measles cases, or were a review, abstract, letter, editorial or brief report.

151  
152 Following full text review, for each study that met our inclusion and exclusion criteria, we  
153 extracted the following data: study setting, study design and type (including information on  
154 planned, achieved (i.e., how many persons were reached via sampling), and reported (i.e., how  
155 many persons were represented in final study metrics) sample sizes), population demographics  
156 (including income and representativeness), type of specimen collected, serologic assay details  
157 (including type, name, and inclusion of a reference preparation), antibody threshold used for  
158 seropositivity and/or seroprotection (if relevant), and measures of proportion seropositive,  
159 seronegative, or indeterminate with accompanying uncertainty. We extracted data into a  
160 Microsoft Excel workbook and for seroprevalence measure, we recorded the most granular  
161 levels for relevant strata (i.e., by age, vaccination status, infection history, etc.) presented in  
162 each study.

### 163 *Bias assessment*

164  
165 Following extraction of all available data, we developed a comprehensive bias assessment tool  
166 and applied the tool to characterize the level of bias across each study. Our tool, modified from  
167 the ROBINS-I tool<sup>12</sup>, considers bias across the following categories, with associated indicators:  
168 study selection of participants, measurement tool and classification of immunity, and reporting of  
169 results (Supplementary Figures 1-3). We classified the level of bias across each category to be  
170 either low, moderate, severe, or critical. We then finally assessed the overall level of bias as  
171 low, moderate, severe, or critical for each study by taking the mean score of the category-  
172 specific classifications.

173  
174 To assess bias among study selection of participants, we considered whether the study design  
175 used a random process for sample selection, if a study relied on a convenience sample, was  
176 restricted only to a subset of the population (e.g., only included pregnant women or cancer  
177 survivors), and reporting of planned, achieved, specimen, and final sample sizes. To assess the  
178 level of bias among the measurement tool and classification of immunity, we considered  
179 whether assay protocol, name, or references were provided, if internal or external validation or  
180 quality control was performed, and if there were other known factors known to decrease  
181 sensitivity or specificity. These factors included using oral fluid as specimens<sup>13</sup>, using a  
182 hemagglutination inhibition (HI/HAI) assay<sup>13</sup>, or using the Whittaker enzyme-linked  
183 immunosorbent assay (ELISA)<sup>14</sup>. Last, for bias among reporting of results, we considered

184 whether a known threshold was used for determining protective titer levels, including metrics of  
185 uncertainty with seroprevalence estimates, and, if an enzyme immunoassay (EIA) or ELISA was  
186 used, whether and how equivocal results were handled and reported.

187  
188 We characterized the overall level of bias in each study using the following criteria. For each  
189 category of bias studies were given a numeric score: low bias was assigned a score of 1,  
190 moderate a score of 2, severe a score of 3, and critical a score of 4. We took the mean of  
191 scores across all three categories. Studies with a mean score below 1.5 were characterized to  
192 have low overall bias, between 1.5 and 2.5 to have moderate overall bias, between 2.5 and 3 to  
193 have severe bias, and more than three to have critical bias.

194  
195 We converted all metrics reported to proportion seropositive and then used R version 5.4.0 to  
196 compute summary metrics and make figures. For studies reporting seropositive and  
197 indeterminate/equivocal results independently, we did not include indeterminate results in the  
198 numerator of our overall seroprevalence calculation. We compared data availability by decade  
199 and bias level. We additionally investigated bias levels across time and region and assessed  
200 bias levels across locations with higher and lower first-dose measles-containing vaccine (MCV1)  
201 coverage<sup>15</sup> and higher and lower estimated annual measles incidence<sup>16</sup> in the year from which  
202 study data was collected.

203  
204 *Role of the funding source*

205 The Bill & Melinda Gates Foundation, Gavi, the Vaccine Alliance and the US National Institutes  
206 of Health had no role in study design, data collection, data analysis, data interpretation, or the  
207 writing of the report. All authors had access to the data and the corresponding author had final  
208 responsibility to decide to submit for publication.

## 209 210 Results

### 211 *Systematic review*

212 From our search, we identified 2032 studies for screening (Figure 1). Following screening, we  
213 excluded 1116 studies that did not meet our search criteria. For the remaining 916 studies, we  
214 assessed the full-text articles for inclusion. We identified 221 studies for inclusion and extracted  
215 information on measles seroprevalence, study design, and seroassay (link to zenodo file once  
216 uploaded). Studies were published between 1962 to 2021, including seroprevalence surveys  
217 conducted between 1953 and 2019.

218  
219 Among 182,789 persons sampled across all studies, age groups, and years, the crude mean  
220 measles seroprevalence was 78.00% (SD: 19.29%) and median seroprevalence was 84.00%  
221 (IQR: 72.75 – 91.66%).

222 Across regions of the World Health Organization (WHO), there were 43 studies containing data  
223 from the African Region, 47 from the Eastern Mediterranean Region, 35 from the European  
224 Region, 25 from the Region of the Americas, 20 from the South-East Asia Region, and 73 from  
225 the Western Pacific Region (Figure 2). There were 24 studies that represented data collected  
226 before 1980, 32 studies from 1980 to 1989, 29 studies from 1990 to 1999, 55 studies from 2000  
227 to 2009, and 83 studies from 2010 to 2019. 178 studies (80.5%) contained age stratified results  
228 across 531 unique age ranges.

### 229 230 *Bias assessment*

231 Table 1 shows results of our bias assessment for each included study. For overall bias, we  
232 classified bias as low in 12 (5.4%) studies moderate in 129 (58.3%), severe in 58 (26.2%) and  
233 critical in 22 (10.0%). No studies had low or critical bias across all the categories of study

234 selection of participants, measurement tool and classification of immunity, and reporting of  
235 results (Table 1).

236  
237 For study selection of participants, we identified 15 studies with low bias, 181 with moderate  
238 bias, 23 with severe bias, and 2 with critical bias. 81 studies used a random sample selection  
239 method. 117 studies with convenience samples used a restricted, non-representative sample  
240 (i.e., only among a specific subgroup of the population, such as persons living with HIV). 2  
241 studies did not report the final sample size, and of the 81 samples that used a random sample  
242 selection method, 45 reported the planned sample size, and 15 additionally reported the  
243 planned, achieved, and specimen sample sizes.

244  
245 In measurement assay and classification of immunity, we identified 19 studies with low bias, 130  
246 with moderate bias, 46 with severe bias, and 26 with critical bias. Across the three categories of  
247 bias assessment, measurement assay and classification of immunity had the highest number of  
248 studies classified as having critical bias, largely due to absence of information on assay protocol  
249 details, commercial kit name or other appropriate citation describing the underlying methods.  
250 195 studies provided details on the assay protocol or commercial kit name, and 25 studies  
251 conducted internal or external validation or quality control. 6 studies specified that samples were  
252 oral fluid specimens and 30 studies specified that samples collected were dried blood spots.

253  
254 54 studies used an HI/HAI assay, 139 used an EIA or ELISA, 13 used a plaque reduction  
255 neutralization test (PRNT), 6 used a multiplex bead assay, and 11 used other or undescribed  
256 assay types. We noted changing temporal trends of types of seroassays used. While EIA,  
257 ELISA and PRNT assays were used in even distribution across all studies examined, there was  
258 no study published after 2001 that utilized an HI/HAI assay, and all studies using a multiplex  
259 immunofluorescent assay were conducted in 2013 or later.

260  
261 We identified 20 studies with low bias, 63 with moderate bias, 70 with severe bias, and 18 with  
262 critical bias in reporting of results. 155 studies reported a threshold to define seroprevalence.  
263 Among the 139 studies that used an EIA or ELISA, 30 studies reported equivocal results  
264 separately or included with seropositivity results and 1 study excluded equivocal results and  
265 they were less than 5% of the overall sample. Finally, 59 studies reported metrics of  
266 seropositivity or seronegativity with any accompanying uncertainty.

267  
268 *Seroprevalence trends*

269 The crude median seroprevalence estimates from studies in the Western Pacific Region was  
270 88.3% (IQR: 79.2 – 93.4%), in the Eastern Mediterranean Region was 87.2% (IQR: 81.3 –  
271 93.2%), the European Region was 82.0% (IQR: 77.8 – 89.0%), in the Region of the Americas  
272 was 78.4% (IQR: 60.7 – 93.0%), in the African Region was 77.6% (IQR: 60.7 – 89.9%), and in  
273 the South-East Asia Region was 66.8% (IQR: 47.4 – 88.4%). Trends in seroprevalence and bias  
274 vary by decade (Figure 3). The median seroprevalence was lower in studies from 2010 to 2019  
275 than those conducted before 1980 (i.e., the pre-vaccination era). Crude seroprevalence from  
276 studies conducted before 1980 was 90.5% (IQR: 67.8 – 93.3%), from 1980 to 1989 was 78.6%  
277 (IQR: 57.8 – 90.7%), from 1990 to 1999 was 88.3% (IQR: 60.7 – 92.6%), from 2000 to 2010  
278 was 80.4% (IQR: 65.6 – 88.2%), and from 2010 to 2019 was 84.6% (IQR: 78.3 – 92.9%).  
279 Among 31 country-years with studies containing critical bias, 23 (74%) occurred in earlier time  
280 periods (i.e., before 1980 and between 1980 and 1989). In the 159 country-years with studies  
281 containing low or moderate bias, 96 (60%) have occurred between 2010 and 2019.

282  
283 We additionally compared the overall bias levels for each country-year of the studies to the  
284 MCV1 coverage and measles incidence from the same country-year (Figure 4). Generally,

285 studies in countries and years in 1980 or later with lower MCV1 coverage and higher measles  
286 incidence had more bias compared to studies from countries and years with higher MCV1  
287 coverage and lower measles incidence ( $p < 0.001$ , in proportional odds logistic regression  
288 models for both MCV1 coverage and incidence). Among 109 studies from countries and years  
289 with MCV1 coverage greater than 80%, 93 (85%) had low or moderate overall bias, and from  
290 the 58 studies from countries and years with MCV1 coverage of 80% or lower, 34 (58%) had  
291 low or moderate overall bias. A similar trend persisted across studies in countries and years  
292 with high incidence – 103 of 122 (84%) studies in countries and years with average annual  
293 reported measles incidence less than 5 per 1000 persons had low or moderate overall bias, and  
294 24 of 49 (49%) of studies in countries with annual measles incidence of 5 per 1000 persons or  
295 greater had low or moderate overall bias.  
296

## 297 Discussion

298 To identify the scope of measles seroprevalence data, we conducted an updated systematic  
299 review of serosurveys to identify primary data sources and characterized underlying bias across  
300 these studies. The resulting data repository from our investigation along with information on  
301 factors related to underlying bias per study could contribute to analyses of measles dynamics  
302 among low- and middle-income countries. We identified serosurveys available in each decade,  
303 WHO region, and across a wide variety of ages, which could be useful when modelling location-  
304 , time-, and age-specific estimates of measles transmission and susceptibility. Despite this  
305 variation, there were locations for which very few or no serosurveys have been conducted –  
306 mainly in the African Region – which contribute to knowledge and data gaps to inform high-  
307 quality modelling and analyses.  
308

309 Additionally, our study provides insight to issues to consider when designing and reporting a  
310 seroprevalence study to ensure that the highest quality surveys are conducted and that  
311 complete, accurate and transparent reports are generated. The number of available measles  
312 seroprevalence studies has increased in the last few decades compared to periods before the  
313 introduction of national measles vaccination programmes in LMICS. This trend provides the  
314 opportunity for researchers to examine the impact of vaccination programs on ongoing  
315 susceptibility within the population represented in each study. However, we found that locations  
316 with high annual measles incidence and lower MCV1 coverage tend to have not only less  
317 studies conducted, but also higher bias – this is understandable given that coverage tends to be  
318 lower in the most difficult settings such as remote and/or conflict-affected regions, where  
319 surveys are especially challenging to conduct. Research and programmatic teams planning  
320 seroprevalence studies, especially among persons living in these vulnerable communities, could  
321 use the framework presented in this study as a starting point to determining the feasibility and  
322 cost of conducting a high-quality seroprevalence survey and consider alternative ways to invest  
323 the funds (e.g., in strengthening ongoing surveillance of coverage and disease incidence).  
324

325 More recently, there have been examples of high-quality serosurveys, such as a nationally  
326 representative survey in Zambia<sup>17</sup>, that have been conducted and used for informative  
327 modelling. Given the complexity, time, and expense of these surveys, it is worthwhile to make  
328 the most of high-quality surveys that are being conducted for different infections and funded  
329 through a variety of different programs. This serosurvey in Zambia, for example, leveraged  
330 residual sera from the Zambia Population-Based HIV Impact Assessment (ZAMPHIA) study<sup>18</sup>  
331 originally collected to estimate HIV incidence and viral load. Applications of such data extend to  
332 innovative modelling efforts to estimate subnational and age-specific seroprevalence estimates  
333 as well as national level outbreak risk<sup>17</sup>. That study serves as an example of the potential to



334 leverage other major population surveys and to use high quality seroprevalence estimates to  
335 inform evidence for decision making.

336  
337 More studies had low or moderate bias compared to severe or critical bias among the  
338 categories of selection of study participants and measurement tool and classification of  
339 immunity. For the category of reporting of results, more studies had severe or critical bias levels  
340 than low or moderate bias levels. Overall, we found that less than 10% of studies had low  
341 overall bias, suggesting that the quality of conduct and reporting of seroprevalence studies has  
342 substantial potential for improvement.

343  
344 While interpreting seroprevalence estimates identified by our review, it is essential to also  
345 consider the associated sensitivity and specificity of the seroassays used in studies along with  
346 the route of induced immunity (i.e., from vaccination or natural infection). For example, HI/HAI  
347 assays are often less sensitive than other types<sup>13</sup>. If HI/HAI assays are used in a population with  
348 mainly vaccine-induced immunity, seroprevalence results may be underestimated. However,  
349 since HI/HAI assays were historically used more frequently, during an era with less vaccine-  
350 derived immunity and subsequently higher natural immunity affording higher antibody levels,  
351 assay sensitivity might not be as important to consider. In our bias assessment in the category  
352 of measurement tool and classification of immunity, we defined factors that influence assay  
353 specificity and sensitivity as either (1) using an HI/HAI assay, (2) using the Whittaker  
354 commercial ELISA kit, or (3) using oral fluid samples. However, the utility of this specific  
355 contribution to our bias assessment might be subject to the specific study setting, vaccination  
356 program implementation and success, and underlying measles epidemiology.

357  
358 Our study has several limitations. First, we were unable to fully synthesize results of our  
359 systematic review in a meta-analysis or other stratified analysis by age, location, or year. This  
360 was due to the differing study populations, regions, time periods, and age groups presented in  
361 studies identified in this review as well as the varying degrees of bias characterized to be  
362 present across studies. These results can serve as the basis for future models that synthesize  
363 the data while also accounting for underlying measles infection dynamics, vaccination coverage  
364 and population structures for each individual study setting, which was out of the scope of our  
365 analysis.

366  
367 Secondly, we were constrained by the information reported in each publication. Without  
368 adequate reporting, we assumed the highest level of associated bias whenever appropriate. For  
369 example, if a study did not specifically note if they used an international reference preparation,  
370 we assumed they did not use one. This may have led us to classify studies as having higher  
371 bias in relevant categories than might have been the case if all available information had been  
372 included in the publication – it possible that some details were omitted to meet restrictions on  
373 word counts, for example. As such, there might be great utility in the widespread use of  
374 standardized reporting expectations for ongoing and future seroprevalence studies.

375  
376 Next, we did not consider sample size in our assessment of bias. Since the impact of sample  
377 size on the reliability of point estimates from seroprevalence studies should be reflected in the  
378 provided uncertainty interval, we considered the inclusion of such in our bias assessment. We  
379 did not however further assess the implications of smaller or wide interval spans of if they were  
380 presented or whether point estimates or uncertainty intervals were adjusted or standardized for  
381 population demographics or other factors. Finally, there are likely additional sources of bias that  
382 are more difficult to ascertain objectively, such as potential issues with specimen storage and  
383 laboratory capacity, practices, and quality.

384

385 Our study strengthens the understanding of the availability and bias among measles  
386 seroprevalence studies in low- and middle-income countries by identifying primary sources of  
387 measles seroprevalence studies and conducting a bias assessment of the associated data. Our  
388 framework for assessing bias could provide a foundation for further work by relevant agencies  
389 and interested partners to develop a tool for use in planning and reporting future surveys. This  
390 work can be a vital tool to be used during modelling exercises, planning immunization-based  
391 interventions, and ultimately, to make informed decisions to reduce preventable measles  
392 morbidity and mortality.

393

## 394 Contributions

395 ANS, MJ and JFM conceived and planned this study. ANS, FC, DR, MJ and JFM designed the  
396 bias assessment framework. ANS, HF and IP screened and extracted studies. ANS made  
397 tables and figures. ANS wrote the first draft of the manuscript and all authors contributed to  
398 subsequent revisions.

399

## 400 References

401

- 402 1 Minta, A. A. *et al.* Progress Toward Regional Measles Elimination - Worldwide, 2000-2021.  
403 *MMWR Morb Mortal Wkly Rep* **71**, 1489-1495 (2022).  
404 <https://doi.org/10.15585/mmwr.mm7147a1>
- 405 2 Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a  
406 systematic analysis for the Global Burden of Disease Study 2019. *Lancet* **396**, 1204-1222 (2020).  
407 [https://doi.org/10.1016/s0140-6736\(20\)30925-9](https://doi.org/10.1016/s0140-6736(20)30925-9)
- 408 3 Keja, K., Chan, C., Hayden, G. & Henderson, R. H. Expanded programme on immunization. *World*  
409 *Health Stat Q* **41**, 59-63 (1988).
- 410 4 Hughes, S. L. *et al.* The effect of time since measles vaccination and age at first dose on measles  
411 vaccine effectiveness - A systematic review. *Vaccine* **38**, 460-469 (2020).  
412 <https://doi.org/10.1016/j.vaccine.2019.10.090>
- 413 5 Kumru, O. S. *et al.* Vaccine instability in the cold chain: mechanisms, analysis and formulation  
414 strategies. *Biologicals* **42**, 237-259 (2014). <https://doi.org/10.1016/j.biologicals.2014.05.007>
- 415 6 Mutsaerts, E. *et al.* Safety and Immunogenicity of Measles Vaccination in HIV-Infected and HIV-  
416 Exposed Uninfected Children: A Systematic Review and Meta-Analysis. *EClinicalMedicine* **1**, 28-  
417 42 (2018). <https://doi.org/10.1016/j.eclinm.2018.06.002>
- 418 7 Winter, A. K. *et al.* Benefits and Challenges in Using Seroprevalence Data to Inform Models for  
419 Measles and Rubella Elimination. *J Infect Dis* **218**, 355-364 (2018).  
420 <https://doi.org/10.1093/infdis/jiy137>
- 421 8 Cutts, F. T. & Hanson, M. Seroepidemiology: an underused tool for designing and monitoring  
422 vaccination programmes in low- and middle-income countries. *Trop Med Int Health* **21**, 1086-  
423 1098 (2016). <https://doi.org/10.1111/tmi.12737>
- 424 9 Lutz, C. S. *et al.* Comparison of measles IgG enzyme immunoassays (EIA) versus plaque  
425 reduction neutralization test (PRNT) for measuring measles serostatus: a systematic review of  
426 head-to-head analyses of measles IgG EIA and PRNT. *BMC Infect Dis* **23**, 367 (2023).  
427 <https://doi.org/10.1186/s12879-023-08199-8>
- 428 10 Hutse, V. *et al.* Oral fluid for the serological and molecular diagnosis of measles. *Int J Infect Dis*  
429 **14**, e991-997 (2010). <https://doi.org/10.1016/j.ijid.2010.06.009>
- 430 11 World Bank. *The World by Income and Region*, <[https://datatopics.worldbank.org/world-](https://datatopics.worldbank.org/world-development-indicators/the-world-by-income-and-region.html)  
431 [development-indicators/the-world-by-income-and-region.html](https://datatopics.worldbank.org/world-development-indicators/the-world-by-income-and-region.html)> (2021).

- 432 12 Sterne, J. A. *et al.* ROBINS-I: a tool for assessing risk of bias in non-randomised studies of  
433 interventions. *BMJ* **355**, i4919 (2016). [https://doi.org:10.1136/bmj.i4919](https://doi.org/10.1136/bmj.i4919)
- 434 13 World Health Organization. *Manual for the Laboratory-based Surveillance of Measles, Rubella,*  
435 *and Congenital Rubella Syndrome*, <[https://cdn.who.int/media/docs/default-](https://cdn.who.int/media/docs/default-source/immunization/vpd_surveillance/lab_networks/measles_rubella/manual/chapter-9.pdf)  
436 [source/immunization/vpd\\_surveillance/lab\\_networks/measles\\_rubella/manual/chapter-9.pdf](https://cdn.who.int/media/docs/default-source/immunization/vpd_surveillance/lab_networks/measles_rubella/manual/chapter-9.pdf)> (  
437 14 Cutts, F. T. *et al.* Immunogenicity of high-titer Edmonston-Zagreb measles vaccine in human  
438 immunodeficiency virus-infected children in Kinshasa, Zaire. *J Infect Dis* **167**, 1418-1421 (1993).  
439 [https://doi.org:10.1093/infdis/167.6.1418](https://doi.org/10.1093/infdis/167.6.1418)
- 440 15 WHO. *WHO/UNICEF estimates of national immunization coverage*,  
441 <[https://www.who.int/teams/immunization-vaccines-and-biologicals/immunization-analysis-](https://www.who.int/teams/immunization-vaccines-and-biologicals/immunization-analysis-and-insights/global-monitoring/immunization-coverage/who-unicef-estimates-of-national-immunization-coverage)  
442 [and-insights/global-monitoring/immunization-coverage/who-unicef-estimates-of-national-](https://www.who.int/teams/immunization-vaccines-and-biologicals/immunization-analysis-and-insights/global-monitoring/immunization-coverage/who-unicef-estimates-of-national-immunization-coverage)  
443 [immunization-coverage](https://www.who.int/teams/immunization-vaccines-and-biologicals/immunization-analysis-and-insights/global-monitoring/immunization-coverage/who-unicef-estimates-of-national-immunization-coverage)> (2022).
- 444 16 Eilertson, K. E., Fricks, J. & Ferrari, M. J. Estimation and prediction for a mechanistic model of  
445 measles transmission using particle filtering and maximum likelihood estimation. *Stat Med* **38**,  
446 4146-4158 (2019). [https://doi.org:10.1002/sim.8290](https://doi.org/10.1002/sim.8290)
- 447 17 Carcelen, A. C. *et al.* Leveraging a national biorepository in Zambia to assess measles and rubella  
448 immunity gaps across age and space. *Sci Rep* **12**, 10217 (2022). [https://doi.org:10.1038/s41598-](https://doi.org/10.1038/s41598-022-14493-3)  
449 [022-14493-3](https://doi.org/10.1038/s41598-022-14493-3)
- 450 18 Ministry of Health Zambia. Zambia Population-based HIV Impact Assessment (ZAMPHIA) 2016:  
451 Final Report. (Lusaka, Ministry of Health, February 2019).
- 452

453 **Tables**

454

455 **Table 1. Overall and categorical bias classifications.**

456 Results of bias assessment in each of three categories (study selection of participants,  
457 measurement tool and classification of immunity, and reporting of results), and mean level of  
458 bias per study.

459

Level of bias	Mean	Study selection of participants	Measurement tool and classification of immunity	Reporting of results
Low	12	15	19	20
Moderate	129	181	130	63
Severe	58	23	46	70
Critical	22	2	26	18

460


461

462


463 **Figures**

464  
465  
466  
467  
468  
469  
470  
471  
472  
473  
474  
475  
476  
477  
478  
479  
480  
481  
482  
483  
484  
485  
486  
487  
488  
489  
490  
491  
492  
493  
494  
495  
496  
497  
498  
499  
500  
501  
502  
503  
504

**Figure 1. PRISMA diagram.**




505 **Figure 2. Number of serosurveys with data included per country.**  
506 Map of number of studies per country with available data identified by systematic review.  
507




508  
509

510 **Figure 3. Measles seroprevalence by time period and overall bias level.**  
511 Beeswarm plot of measles seroprevalence by time period. Each point represents one country-  
512 year of data per study and are colored by overall bias level. Black lines represent the median  
513 observation across each decade.  
514



515

516 **Figure 4. Overall bias level by MCV1 coverage and annual measles incidence.**  
517 Each point represents each country-year represented across all studies, colored by overall bias  
518 level, by MCV1 coverage and annual estimated measles incidence.  
519



520